The London Company Mid Cap portfolio returned 9.4% year-to-date vs. a 15.3% increase in the Russell Midcap Index.
Operator Thank you for standing by, and welcome to the Lineage fourth quarter 2024 earnings conference call. [Operator ...
Partnerships with LinkedIn, Okta, and Uber bolster Clear Secure's CLEAR Verify enterprise segment. Read why YOU stock is a ...
1d
GOBankingRates on MSNHow To Invest in the ThoughtSpot IPO: A Beginner’s GuideThoughtSpot offers cloud-based solutions to finding and analyzing data in an accurate, rapid, user-friendly manner. Launching ...
Discover ISSC's strategic shift to military markets, strong growth, and compelling valuation—positioned for long-term ...
6d
Hosted on MSNNSDL IPO Date: NSE, IDBI, HDFC Bank to reduce stake in OFS - Public issue launch, listing timelineA senior company official on Thursday told news agency PTI that NSDL is targeting to launch its much-awaited Rs 3,000 crore IPO soon. Stating that the company is expected to launch its public issue by ...
Taking your company public through an IPO is a crucial step, presenting a unique opportunity to benefit both your business and its investors. Explore the Nasdaq IPO Academy, a program tailored to ...
Learn about AEye's transformative Q4 2024, featuring Apollo LiDAR's launch and production scaling. Discover earnings outcomes and OEM engagement insights.
Despite lower volumes, adjusted EBITDA increased by $40M, with operating margins improving by 60 basis points due to strong operational performance and cost reduction initiatives. The $300M cost ...
QQQ is a tech-heavy ETF that provides a diversified bet on AI and the quality of top US Mag7 plays. Learn more about QQQ and ...
6d
ET Now on MSNNSDL IPO Expected Date: ‘We are rushing against…’ – What senior official REVEALED on depository’s Rs 3,000-cr issue launch timelineReplying to a specific query on the timeline for NSDL IPO, the official said, as quoted by PTI, “Our dates are expiring next ...
Nurix Therapeutics, Inc. stock slid 40% after promising NX-5948 results in CLL. NX-5948 shows efficacy in heavily pre-treated ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results